XML 47 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Activities (Notes)
 12 Months Ended
Dec. 31, 2017
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure [Text Block]
Restructuring Activities
We have implemented a number of cost reduction or avoidance actions, including headcount reductions and facility closures and relocations primarily relating to the consolidation of certain of our facilities in China, the Buffalo BioMedical respiratory consolidation, and relocation of the corporate headquarters. The Buffalo BioMedical respiratory facility consolidation into Ball Ground, Georgia, was completed during the first quarter of 2017, and the reduction in force was completed in the third quarter of 2017. The E&C Wuxi, China facility consolidation was completed during the second quarter of 2017, and the D&S China facility consolidation was substantially completed during the fourth quarter of 2017. Our corporate headquarters move from Garfield Heights, Ohio to Ball Ground, Georgia (which was officially effective October 26, 2017) was substantially completed during the third quarter of 2017, and our Garfield Heights lease commitment ended on December 31, 2017.
The following table is a summary of the severance and other restructuring costs, which included employee-related costs, facility rent and exit costs, relocation, recruiting, travel and other, for the years ended December 31, 2017, 2016 and 2015:
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Severance:
 
 
 
 
 
 
Cost of sales
 
$
0.8

 
$
4.2

 
$
2.2

Selling, general, and administrative expenses
 
3.8

 
5.8

 
5.2

Total severance costs
 
$
4.6

 
$
10.0

 
$
7.4

Other restructuring:
 
 
 
 
 
 
Cost of sales
 
$
4.4

 
$
0.2

 
$
1.4

Selling, general, and administrative expenses
 
6.6

 
0.7

 
3.4

Total other restructuring costs
 
$
11.0

 
$
0.9

 
$
4.8

 
 
 
 
 
 
 
Total restructuring costs
 
$
15.6

 
$
10.9

 
$
12.2


We currently do not expect any significant severance or restructuring charges in 2018. We are closely monitoring our end markets and order rates and will continue to take appropriate and timely actions as necessary.
The following tables summarize our restructuring activities for the years ended 2017, 2016 and 2015:
 
Twelve Months Ended December 31, 2017
 
Energy & Chemicals
 
Distribution & Storage
 
BioMedical
 
Corporate
 
Total
Balance as of December 31, 2016
$
0.1

 
$
2.9

 
$
1.3

 
$
3.0

 
$
7.3

Restructuring costs
2.4

 
2.2

 
5.0

 
6.0

 
15.6

Cash payments
(2.5
)
 
(3.9
)
 
(6.0
)
 
(7.9
)
 
(20.3
)
Acquired restructuring reserve
0.2

 
—

 
—

 
—

 
0.2

Balance as of December 31, 2017
$
0.2

 
$
1.2

 
$
0.3

 
$
1.1

 
$
2.8

 
Twelve Months Ended December 31, 2016
 
Energy & Chemicals
 
Distribution & Storage
 
BioMedical
 
Corporate
 
Total
Balance as of December 31, 2015
$
1.1

 
$
3.4

 
$
0.4

 
$
0.9

 
$
5.8

Restructuring costs
1.0

 
3.8

 
1.9

 
4.2

 
10.9

Cash payments
(2.0
)
 
(4.3
)
 
(1.0
)
 
(2.1
)
 
(9.4
)
Balance as of December 31, 2016
$
0.1

 
$
2.9

 
$
1.3

 
$
3.0

 
$
7.3

 
Twelve Months Ended December 31, 2015
 
Energy & Chemicals
 
Distribution & Storage
 
BioMedical
 
Corporate
 
Total
Balance as of December 31, 2014
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Restructuring costs
1.4

 
7.7

 
1.8

 
1.3

 
12.2

Cash payments
(0.3
)
 
(4.3
)
 
(1.4
)
 
(0.4
)
 
(6.4
)
Balance as of December 31, 2015
$
1.1

 
$
3.4

 
$
0.4

 
$
0.9

 
$
5.8